Cargando…
Drug Usage Evaluation of Dapsone
Dapsone has been the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. It is also widely used by dermatologists in varied skin conditions like dermatitis herpetiformis, bullous pemphigoid, Behcet's disease, lupus erythematous and a...
Autores principales: | , , , , , , |
---|---|
Formato: | Texto |
Lenguaje: | English |
Publicado: |
Medknow Publications
2009
|
Materias: | |
Acceso en línea: | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865824/ https://www.ncbi.nlm.nih.gov/pubmed/20502558 http://dx.doi.org/10.4103/0250-474X.57301 |
_version_ | 1782180880053174272 |
---|---|
author | Kannan, G. Vasantha, J. Rani, N. Vanitha Thennarasu, P. Kousalya, K. Anuradha, P. Reddy, C. Umamaheswara |
author_facet | Kannan, G. Vasantha, J. Rani, N. Vanitha Thennarasu, P. Kousalya, K. Anuradha, P. Reddy, C. Umamaheswara |
author_sort | Kannan, G. |
collection | PubMed |
description | Dapsone has been the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. It is also widely used by dermatologists in varied skin conditions like dermatitis herpetiformis, bullous pemphigoid, Behcet's disease, lupus erythematous and a host of other skin diseases. Hence an attempt has been made to review the utilization and qualitative evaluation of dapsone over a period of 6 months in a tertiary care teaching hospital. The study consisted of 80 patients (54 leprosy and 26 non-leprosy patients), prescribed with dapsone 100 mg oral once daily. The prescribing patterns of dapsone in leprosy and other dermatological conditions (non-leprosy) were analyzed and the safety, efficacy and appropriateness of the doses prescribed were reviewed. The adverse drug reactions observed in the study population were type I Lepra reactions, gastrointestinal side effects (abdominal pain and anorexia), peripheral neuropathy, other nervous side effects (insomnia, headache and vertigo) and other adverse reactions (fever and tinnitus). Patient information leaflets were distributed to patients to educate on the appropriate use of dapsone. |
format | Text |
id | pubmed-2865824 |
institution | National Center for Biotechnology Information |
language | English |
publishDate | 2009 |
publisher | Medknow Publications |
record_format | MEDLINE/PubMed |
spelling | pubmed-28658242010-05-25 Drug Usage Evaluation of Dapsone Kannan, G. Vasantha, J. Rani, N. Vanitha Thennarasu, P. Kousalya, K. Anuradha, P. Reddy, C. Umamaheswara Indian J Pharm Sci Short Communication Dapsone has been the principal drug in a multidrug regimen recommended by the World Health Organization for the treatment of leprosy. It is also widely used by dermatologists in varied skin conditions like dermatitis herpetiformis, bullous pemphigoid, Behcet's disease, lupus erythematous and a host of other skin diseases. Hence an attempt has been made to review the utilization and qualitative evaluation of dapsone over a period of 6 months in a tertiary care teaching hospital. The study consisted of 80 patients (54 leprosy and 26 non-leprosy patients), prescribed with dapsone 100 mg oral once daily. The prescribing patterns of dapsone in leprosy and other dermatological conditions (non-leprosy) were analyzed and the safety, efficacy and appropriateness of the doses prescribed were reviewed. The adverse drug reactions observed in the study population were type I Lepra reactions, gastrointestinal side effects (abdominal pain and anorexia), peripheral neuropathy, other nervous side effects (insomnia, headache and vertigo) and other adverse reactions (fever and tinnitus). Patient information leaflets were distributed to patients to educate on the appropriate use of dapsone. Medknow Publications 2009 /pmc/articles/PMC2865824/ /pubmed/20502558 http://dx.doi.org/10.4103/0250-474X.57301 Text en © Indian Journal of Pharmaceutical Sciences http://creativecommons.org/licenses/by/2.0/ This is an open-access article distributed under the terms of the Creative Commons Attribution License, which permits unrestricted use, distribution, and reproduction in any medium, provided the original work is properly cited. |
spellingShingle | Short Communication Kannan, G. Vasantha, J. Rani, N. Vanitha Thennarasu, P. Kousalya, K. Anuradha, P. Reddy, C. Umamaheswara Drug Usage Evaluation of Dapsone |
title | Drug Usage Evaluation of Dapsone |
title_full | Drug Usage Evaluation of Dapsone |
title_fullStr | Drug Usage Evaluation of Dapsone |
title_full_unstemmed | Drug Usage Evaluation of Dapsone |
title_short | Drug Usage Evaluation of Dapsone |
title_sort | drug usage evaluation of dapsone |
topic | Short Communication |
url | https://www.ncbi.nlm.nih.gov/pmc/articles/PMC2865824/ https://www.ncbi.nlm.nih.gov/pubmed/20502558 http://dx.doi.org/10.4103/0250-474X.57301 |
work_keys_str_mv | AT kannang drugusageevaluationofdapsone AT vasanthaj drugusageevaluationofdapsone AT raninvanitha drugusageevaluationofdapsone AT thennarasup drugusageevaluationofdapsone AT kousalyak drugusageevaluationofdapsone AT anuradhap drugusageevaluationofdapsone AT reddycumamaheswara drugusageevaluationofdapsone |